AnaptysBio, Roche sign agreement for development of novel antibody therapeutics

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced it has signed an agreement with Roche for the development of novel antibody therapeutics.

“AnaptysBio’s proprietary SHM platform provides a powerful new approach for evolving existing antibodies to meet challenging therapeutic design goals such as those specified by Roche”

Under the terms of the agreement, AnaptysBio will be responsible for generating novel antibodies using its proprietary somatic hypermutation (SHM) platform. Roche will receive a worldwide license to develop and commercialize antibodies optimized by AnaptysBio. In addition to a signing fee paid by Roche, AnaptysBio will be eligible to receive milestone payments and royalties upon product sales.

“AnaptysBio’s proprietary SHM platform provides a powerful new approach for evolving existing antibodies to meet challenging therapeutic design goals such as those specified by Roche,” said Tom Smart, chairman and chief executive officer for AnaptysBio. “We look forward to assisting Roche in building its pipeline of product possibilities as we also apply the platform to generate our own novel product candidates.”